NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs, announced it will present today, Nov. 3, 2025, at 9:45 a.m. ET at the Spartan Capital Investor Conference in New York City. The presentation underscores the company's progress in advancing its lead drug candidate, NV-387, toward Phase II human clinical trials, and its broader pipeline targeting multiple viral diseases.
NanoViricides' platform technology, based on TheraCour's nanomedicine, aims to prevent viral escape by designing special purpose nanomaterials for antiviral therapy. The company's lead candidate, NV-387, is a broad-spectrum antiviral drug under development for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections. Another advanced candidate, NV-HHV-1, targets shingles.
The company's business model relies on licensing technology from TheraCour Pharma Inc., with exclusive sub-licensable field licenses for specific viruses. NanoViricides holds worldwide exclusive perpetual licenses for several drugs targeting HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research proves successful.
Investors can find the latest updates on NNVC in the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/cnCIM.
NanoViricides cautions that drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development or result in a successful commercial product.
